Navigation Links
UAB research could improve the prognosis and treatment of lung cancer
Date:1/7/2008

This release is available in Spanish.

A group of scientists led by Professor Xavier Pars of the Department of Biochemistry and Molecular Biology at Universitat Autnoma de Barcelona, has published a research on AKR1B10, an enzyme that is detected in large quantities only in lung cancers, particularly those caused by smoking. This enzyme can appear even when the cancer has not yet developed and lesions are precancerous. Thus this molecule would serve as a good marker in the diagnosis and prognosis of the disease. Moreover, its activity could play a relevant role in the development of lung cancer, which makes the research of great interest for potential future therapeutical applications as well.

According to researchers, both the experiments using test tubes and cell cultures revealed that the enzyme lowers the levels of the most active form of vitamin A (retinoic acid), a strong anticancerous agent. This is achieved by its strong retinal reductase activity, which favours chemical reduction transformation, thus causing retinal, the precursor of retinoic acid, to transform into its least active form, retinol.

Retinoic acid is present in several biological processes - from fetus development to cell proliferation and differentiation - by controlling the expression of certain genes. The reduction of this acid within cells, which is precisely the effect produced by the enzyme under study, is linked directly to the lack of cell differentiation and therefore favours the development of the cancer. In order to discover why the enzyme acts this way, scientists obtained and studied its three-dimensional structure and located the elements responsible for its role in the onset of cancer among smokers. The identification of these structural elements makes it possible to create a specific design for drugs that can treat this disease. In fact, researchers were able to observe how the substance tolrestat, used as an inhibitor of the enzyme AKR1B1, or aldose reductase, responsible for many secondary complications of diabetes, also worked to inhibit the activity of the enzyme AKR1B10. Since both enzymes contain similar structures, research was carried out on its possible applications in the treatment of diabetes.


'/>"/>

Contact: Xavier Pars
xavier.pares@uab.cat
34-935-813-026
Universitat Autonoma de Barcelona
Source:Eurekalert

Related medicine news :

1. Beacon Research Issues TraderNotes on CERP, SEED, OSIR, GFRE, RIMM
2. Research Gets Closer to Origin of Parkinsons Disease
3. amfAR announces inaugural Mathilde Krim Fellowship Awards for AIDS research
4. Researchers use neuroimaging to study ESP
5. UGA researchers receive $9 million in grants to study barriers to effective addiction treatment
6. Jan Marini Skin Research Gives Familiar Logo a Facelift
7. Researchers seek to make cavity-causing bacteria self-destruct
8. Research suggests new treatment suitable for all patients
9. 2007: A Watershed Year for Lupus Research and Education
10. FASgen Announces New Research Discoveries in Lung Cancer
11. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Rosa, California (PRWEB) , ... May 23, 2017 ... ... health management (PHM) technology and a 2017 Best in KLAS category winner, has ... advantageous market position to extend and enhance its technology platform and product offerings,” ...
(Date:5/23/2017)... Rosa, CA (PRWEB) , ... May 23, 2017 , ... ... mosquito season underway in Sonoma County. While officials call for diligence, asking homeowners to ... are looking at potential health concerns. Along with the annoying buzz of mosquitos is ...
(Date:5/23/2017)... ... ... New patients from Charleston, SC, are now welcome to receive a full ... with or without a referral. A full mouth reconstruction can transform the appearance of ... Charleston, SC. Those who suffer from gum disease, misaligned teeth or jaw pain can ...
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a smart ... in an infographic on the current state of anxiety in support of National Mental ... was conducted in April 2017 and benchmarked general anxiety levels as well as identified ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... ... Periodontics, is now welcoming new patients with periodontal plastic surgery treatments, including ... a general dentist. Dr. Green provides these esthetic and functional procedures to help ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
(Date:5/10/2017)... Mass., May 10, 2017 Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended April 1, ... of $1.84 increased 666.7% compared to the prior year ... resulted in a significant gain, while non-GAAP diluted EPS ... 3.2%, or 3.8% in constant currency terms.  Excluding the ...
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
Breaking Medicine Technology: